Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-12-15
1994-08-23
Killos, Paul J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A01N 4350
Patent
active
053408292
ABSTRACT:
Specific aspects of the cellular and humoral immune systems of a mammalian host are regulated by administering to the host a compound having a reactive immunoregulatory conformation whose precise three-dimensional structure is defined herein. Sorbinil, tolrestat, W-3681, and the other immunoregulatory agents described herein possess this reactive conformation and so are therapeutically useful for inhibiting delayed-type hypersensitivity, T-cell proliferation, and B-cell antibody production, without altering the normal cellularity of the immune system or the normal metabolites of the arachidonic acid pathway.
REFERENCES:
patent: 4127665 (1978-11-01), Sarges et al.
patent: 4130714 (1978-12-01), Sarges
patent: 4147795 (1979-04-01), Sarges
patent: 4147797 (1979-04-01), Kelbaugh et al.
patent: 4181728 (1980-11-01), Sarges et al.
patent: 4181729 (1980-01-01), Sarges et al.
patent: 4235911 (1980-11-01), Sarges
patent: 4248882 (1981-02-01), Sarges et al.
patent: 4286098 (1981-08-01), Sarges
patent: 4348526 (1982-09-01), Sarges
patent: 4431828 (1984-02-01), Cue, Jr. et al.
patent: 4966911 (1990-10-01), Clark et al.
Kador, P. F., et al., Anti-allergy drugs as aldose reductase inhibitors, Invest. Ophthalmol. Visual Sci., 1980, Suppl. p. 12.
Smith, S. A., et al., An aldose reductase inhibitor inhibits inflammation, Clin. Res., 34(2):507A, Apr. 1986.
Smith, S. A., et al., An aldose reductase inhibitor inhibits inflammation, Clin. Res., 34(1):48A, 1986.
Cerelli, M. J., et al., Anti-inflammatory and aldose reductase inhibitory activity of some tricyclic arylacetic acids, J. Med. Chem., 29:2347-2351, 1986.
Kador, P. F., et al., Aldose reductase inhibition by anti-allergy drugs, in Enzymology of Carbonyl Metabolism: Aldehyde Dehydrogenase and Aldo/Keto Reductase, Weiner, H., et al., eds., pp. 243-259, Alan R. Liss, N.Y., 1982.
Kador, P. F., and N. E. Sharpless, Pharmacophor requirements of the aldose reductase inhibitor site, Molecular Pharmacology 24:521-531, 1983.
Kissinger, C. R., et al., Crystal structure of sorbinil, C.sub.11 H.sub.9 FN.sub.2 O.sub.3, Acta Cryst. C41:988-990, 1985.
Varughese, K. I., et al., The crystal structure of N-[[6-methoxy-5-(trifluoromethyl)thio-1-naphthalenyl]thioxomethyl]-N-methy lglycine, C.sub.16 H.sub.14 F.sub.3 NO.sub.3 S.sub.2, Can. J. Chem. 61:2137-2140, 1983.
Kissinger, C. R., et al., Structure of WF-3681, 3-2,5-Dihydro-4-hydroxy-5-oxo-3-phenyl-2-furyl)propionic acid, Acta Cryst. C44:512-514, 1988.
Hall, P. C., and K. L. Keim, Anticonvulsant activity of sorbinil and AL-1576: hydantoin-containing aldose reductase inhibitors, Federation Proceedings 46(3):433, 606A, 1987.
Kador, P. F., et al., Differences in the susceptibility of various aldose reductases to inhibition, Docum. Ophthal. Proc. Series 18:117-124, 1979.
Kador, P. F., et al., Sterospecific inhibition of aldose reductase, Eur. J. Med. Chem-Chimica Therapeutica 16(4):293-298, 1981.
Yue, D. K., et al., The effect of aldose reductase inhibition on motor nerve conduction velocity in diabetic rats, Diabetes 31:789-794, 1982.
Sharma, Y. R., and E. Cotlier, Inhibition of lens and cataract aldose reductase by protein-bound anti-rheumatic drugs: salicylate, indomethacin, oxyphenbutazone, sulindac, Exp. Eye Res. 35:21-27, 1982.
Cogan, D. G., et al., Aldose reductase and complications of diabetes, Annals of Internal Medicine 101:82-91, 1984.
Research may alleviate diabetes complications, C&EN:5, 1983.
Kador, P. F., et al., Aldose reductase inhibitors: a potential new class of agents for the pharmacological control of certain diabetic complications, J. Med. Chem. 28(7):842-849, Jul. 1985.
Eaton, R. P., et al., The effect of an aldose reductase inhibiting agent on limited joint mobility in diabetic patients, JAMA 253(10):1437-1440, Mar. 1985.
Hicks, D. R., et al., Tolrestat kinetics, Clin. Pharmacol. Ther. 36(4):493-499, Oct. 1984.
Clark John I.
Farr Andrew G.
Smith Stacia A.
Killos Paul J.
Washington Research Foundation
LandOfFree
Immunoregulatory agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoregulatory agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoregulatory agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-503316